Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

Positive phase III results reported for Ergoset monotherapy

Dec. 24, 1996

Androsorb cleared for clinical trials

Dec. 23, 1996

ImClone and Immunex crosslicense flt3/flk-2 technology

Dec. 23, 1996

Third approval for Parke-Davis HMG-CoA reductase inhibitor

Dec. 23, 1996

Fujisawa synthesizes novel bone resorption inhibitors

Dec. 20, 1996

Grelan, Fournier collaborate on ACAT inhibitors

Dec. 20, 1996

Shaman and Ono expand diabetes collaboration

Dec. 18, 1996

Pamidronate effective against skeletal complications in breast cancer patients

Dec. 18, 1996

Troglitazone hypotensive, hypoglycemic activities established in preclinical model

Dec. 18, 1996

Licenses offered for the use of IL-7 in increasing hematopoietic stem cells

Dec. 17, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Nov. 8, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for November 8, 2024.
Sales balloon for GLP-1 drugs from Novo Nordisk, Eli Lilly
BioWorld
Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide-1 (GLP-1) drugs to treat obesity....
Regulatory actions for Oct. 31, 2024
BioWorld
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Capsida, Electra,...
Australia reimburses Vazkepa a decade after US approval
BioWorld
For the first time, Australians have access to CSL Inc.’s Vazkepa (icosapent ethyl/Vascepa) for managing cardiovascular disease more than a decade after the drug...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.